Last reviewed · How we verify
Vyzulta (LATANOPROSTENE BUNOD)
Vyzulta works by activating the Prostaglandin F2-alpha receptor, which increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure.
Vyzulta (LATANOPROSTENE BUNOD) is a small molecule modality developed by Bausch And Lomb, targeting the Prostaglandin F2-alpha receptor. It is FDA-approved for the treatment of ocular hypertension and open-angle glaucoma. Vyzulta is currently owned by Bausch And Lomb and has a single generic manufacturer. The commercial status of Vyzulta is not off-patent. Key safety considerations include the potential for increased intraocular pressure and conjunctival hyperemia.
At a glance
| Generic name | LATANOPROSTENE BUNOD |
|---|---|
| Sponsor | Bausch Health |
| Target | Prostaglandin F2-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2017 |
Mechanism of action
Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss.
Approved indications
- Ocular hypertension
- Open-angle glaucoma
Common side effects
- conjunctival hyperemia
- eye irritation
- eye pain
- instillation site pain
- conjunctival edema
- vision blurred
- punctate keratitis
- foreign body sensation
Key clinical trials
- A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension (PHASE4)
- Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity (NA)
- Nailfold Capillary Blood Flow With Latanoprost Bunod (PHASE4)
- Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (PHASE2)
- Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT (PHASE3)
- Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vyzulta CI brief — competitive landscape report
- Vyzulta updates RSS · CI watch RSS
- Bausch Health portfolio CI